Logo image
Hospitalizations for Invasive Pneumococcal Disease Among HIV-1-Infected Adolescents and Adults in the United States in the Era of Highly Active Antiretroviral Therapy and the Conjugate Pneumococcal Vaccine
Journal article   Open access   Peer reviewed

Hospitalizations for Invasive Pneumococcal Disease Among HIV-1-Infected Adolescents and Adults in the United States in the Era of Highly Active Antiretroviral Therapy and the Conjugate Pneumococcal Vaccine

Athena P. Kourtis, Sascha Ellington, Pooja Bansil, Denise J. Jamieson and Samuel F. Posner
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, Vol.55(1), pp.128-131
09/01/2010
DOI: 10.1097/QAI.0b013e3181e8ed15
PMID: 20622675
url
https://doi.org/10.1097/QAI.0b013e3181e8ed15View
Published (Version of record) Open Access

Abstract

We describe hospitalization trends of invasive pneumococcal disease (IPD) among HIV-infected adolescents and adults since the introduction of highly active antiretroviral therapy (HAART) and the 7-valent pneumococcal conjugate vaccine (PCV7) in the United States, using the nation-wide inpatient sample. We estimated national trends of IPD hospitalizations during 3 periods: 1994-1995 (pre-HAART/pre-PCV7); 1998-1999 (HAART/pre-PCV7); and 2004-2005 (HAART/early PCV7). The number of IPD hospitalizations among HIV-infected individuals declined 49.2% between 1994/1995 and 2004/2005. Compared with 1994-1995, the adjusted odds ratio for IPD hospitalizations of HIV-infected adolescents and adults in the United States during 2004-2005 was 0.64 (95% confidence interval: 0.54 to 0.77). The decrease was observed after introduction of the PCV7.
Immunology Infectious Diseases Life Sciences & Biomedicine Science & Technology

Details

Logo image